354 related articles for article (PubMed ID: 33289168)
21. Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure.
Waliany S; Lee D; Witteles RM; Neal JW; Nguyen P; Davis MM; Salem JE; Wu SM; Moslehi JJ; Zhu H
Annu Rev Pharmacol Toxicol; 2021 Jan; 61():113-134. PubMed ID: 32776859
[TBL] [Abstract][Full Text] [Related]
22. Cardiotoxicity in cancer immune-checkpoint therapy: Mechanisms, clinical evidence, and management strategies.
Sun JY; Qu Q; Lou YX; Hua Y; Sun GZ; Sun W; Kong XQ
Int J Cardiol; 2021 Dec; 344():170-178. PubMed ID: 34563597
[TBL] [Abstract][Full Text] [Related]
23. Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity.
Guo X; Wang H; Zhou J; Li Y; Duan L; Si X; Zhang L; Fang L; Zhang L
Thorac Cancer; 2020 Feb; 11(2):475-480. PubMed ID: 31849171
[TBL] [Abstract][Full Text] [Related]
24. Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors.
Pirozzi F; Poto R; Aran L; Cuomo A; Galdiero MR; Spadaro G; Abete P; Bonaduce D; Marone G; Tocchetti CG; Varricchi G; Mercurio V
Curr Oncol Rep; 2021 Jan; 23(2):13. PubMed ID: 33415405
[TBL] [Abstract][Full Text] [Related]
25. Role of cardiac MRI in the diagnosis of immune checkpoint inhibitor-associated myocarditis.
Cau R; Solinas C; De Silva P; Lambertini M; Agostinetto E; Scartozzi M; Montisci R; Pontone G; Porcu M; Saba L
Int J Cancer; 2022 Dec; 151(11):1860-1873. PubMed ID: 35730658
[TBL] [Abstract][Full Text] [Related]
26. Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials.
Agostinetto E; Eiger D; Lambertini M; Ceppi M; Bruzzone M; Pondé N; Plummer C; Awada AH; Santoro A; Piccart-Gebhart M; de Azambuja E
Eur J Cancer; 2021 May; 148():76-91. PubMed ID: 33740500
[TBL] [Abstract][Full Text] [Related]
27. Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology.
Chen DY; Huang WK; Chien-Chia Wu V; Chang WC; Chen JS; Chuang CK; Chu PH
J Formos Med Assoc; 2020 Oct; 119(10):1461-1475. PubMed ID: 31444018
[TBL] [Abstract][Full Text] [Related]
28. Update on Immunotherapy Cardiotoxicity: Checkpoint Inhibitors, CAR T, and Beyond.
Patel M; Hudson O; Han J; Kondapalli L; Arora G; Hawi R; Andrikopoulou E; Estes C; Johnson AM; Lenneman C
Curr Treat Options Oncol; 2023 Nov; 24(11):1489-1503. PubMed ID: 37624557
[TBL] [Abstract][Full Text] [Related]
29. Cardiotoxicity associated with immune checkpoint inhibitors and CAR T-cell therapy.
Lipe DN; Rajha E; Wechsler AH; Gaeta S; Palaskas NL; Alhajji Z; Viets-Upchurch J; Chaftari P
Am J Emerg Med; 2021 Dec; 50():51-58. PubMed ID: 34274878
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular Effects of Immune Checkpoint Inhibitors: More Than Just Myocarditis.
Inno A; Tarantini L; Parrini I; Spallarossa P; Maurea N; Bisceglia I; Silvestris N; Russo A; Gori S
Curr Oncol Rep; 2023 Jul; 25(7):743-751. PubMed ID: 37017825
[TBL] [Abstract][Full Text] [Related]
31. Immune checkpoint inhibitor cardiotoxicity: Breaking barriers in the cardiovascular immune landscape.
Zhu H; Ivanovic M; Nguyen A; Nguyen PK; Wu SM
J Mol Cell Cardiol; 2021 Nov; 160():121-127. PubMed ID: 34303670
[TBL] [Abstract][Full Text] [Related]
32. Cardiovascular toxicity of checkpoint inhibitors: review of associated toxicity and design of the Spanish Immunotherapy Registry of Cardiovascular Toxicity.
Zatarain-Nicolás E; Martín P; Márquez Rodas I; Virizuela J; Martín García A; Mitroi C; Cosín Sales J; Barrios V; Sánchez-Cabo F; Ibañez B; de Castro Carpeño J; López Fernández T
Clin Transl Oncol; 2023 Nov; 25(11):3073-3085. PubMed ID: 37227656
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy-Associated Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy: Diagnostic and Management Challenges and Strategies.
Stein-Merlob AF; Rothberg MV; Holman P; Yang EH
Curr Cardiol Rep; 2021 Jan; 23(3):11. PubMed ID: 33483873
[TBL] [Abstract][Full Text] [Related]
34. A comprehensive review on immune checkpoint inhibitors induced cardiotoxicity characteristics and associated factors.
Lessomo FYN; Mandizadza OO; Mukuka C; Wang ZQ
Eur J Med Res; 2023 Nov; 28(1):495. PubMed ID: 37941006
[TBL] [Abstract][Full Text] [Related]
35. Immune Checkpoint Inhibitors-Related Cardiotoxicity.
Konala VM; Adapa S; Aronow WS
Am J Ther; 2020; 27(6):e591-e598. PubMed ID: 31008763
[TBL] [Abstract][Full Text] [Related]
36. Advances in immune checkpoint inhibitors induced-cardiotoxicity.
Li X; Peng W; Wu J; Yeung SJ; Yang R
Front Immunol; 2023; 14():1130438. PubMed ID: 36911712
[TBL] [Abstract][Full Text] [Related]
37. Immune Checkpoint Inhibitor-Associated Myocarditis.
Ganatra S; Neilan TG
Oncologist; 2018 Aug; 23(8):879-886. PubMed ID: 29802219
[TBL] [Abstract][Full Text] [Related]
38. Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure.
Gergely TG; Drobni ZD; Kallikourdis M; Zhu H; Meijers WC; Neilan TG; Rassaf T; Ferdinandy P; Varga ZV
Nat Rev Cardiol; 2024 Jul; 21(7):443-462. PubMed ID: 38279046
[TBL] [Abstract][Full Text] [Related]
39. Pathophysiology of Immune Checkpoint Inhibitor-Induced Myocarditis.
Jiménez-Alejandre R; Ruiz-Fernández I; Martín P
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139654
[TBL] [Abstract][Full Text] [Related]
40. Immune checkpoint inhibitor-related myocarditis: current understanding and potential diagnostic and therapeutic strategies.
Turker I; Johnson DB
Expert Opin Drug Saf; 2023; 22(10):909-919. PubMed ID: 37647330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
